Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274600 | 1.00 | MME (0.47) | MMEALDH1A1HPGDKMT2AFNTA | |
| SCHEMBL29001941 | 0.83 | ALDH1A1 (0.44) | MMEALDH1A1HPGDKMT2AHPGDS | |
| SCHEMBL8621288 | 0.83 | ALDH1A1 (0.44) | MMEALDH1A1HPGDKMT2AHPGDS | |
| SCHEMBL8621292 | 0.83 | ALDH1A1 (0.44) | MMEALDH1A1HPGDKMT2AHPGDS | |
| SCHEMBL10953661 | 0.83 | KMT2A (0.51) | MMEALDH1A1HPGDKMT2A | |
| SCHEMBL10953658 | 0.83 | KMT2A (0.51) | MMEALDH1A1HPGDKMT2A | |
| SCHEMBL17100025 | 0.82 | MME (0.44) | MMEFNTAFNTB | |
| SCHEMBL9638159 | 0.82 | MME (0.44) | MMEFNTAFNTB | |
| SCHEMBL7620487 | 0.82 | APAF1 (0.56) | MMEKMT2AAPAF1 | |
| SCHEMBL7944349 | 0.82 | APAF1 (0.56) | MMEKMT2AAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2015153402-A1 | PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-08 | — | — | WO | disclosed |
| US-9096684-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2015-07-02 | — | — | US | disclosed |
| WO-2015051122-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8987414-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | MME 1195/4885ALDH1A1 3639/4885HPGD 4720/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | MME 3487/4885ALDH1A1 390/4885HPGD 3615/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | MME 3955/4885ALDH1A1 1023/4885HPGD 3471/4885 |
| US-12173291-B2 | Unnatural base pair compositions and methods of use | RNGTT, SPOUT1, NPEPPS | MME 1345/4885ALDH1A1 4434/4885HPGD 4081/4885 |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | RNGTT, SPOUT1, NPEPPS | MME 1345/4885ALDH1A1 4434/4885HPGD 4081/4885 |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | MME 1931/4885ALDH1A1 4570/4885HPGD 2625/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | MME 1389/4885ALDH1A1 3600/4885HPGD 3238/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | MME 598/4885ALDH1A1 4843/4885HPGD 2110/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | MME 1195/4885ALDH1A1 3639/4885HPGD 4720/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | MME 2448/4885ALDH1A1 4459/4885HPGD 1957/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | MME 504/4885ALDH1A1 4764/4885HPGD 2608/4885 |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | MME 2448/4885ALDH1A1 4459/4885HPGD 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.